Savara (SVRA) to Release Earnings on Tuesday

Savara (NASDAQ:SVRA) is projected to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $0.50 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, analysts expect Savara to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Savara Stock Down 2.4%

NASDAQ SVRA traded down $0.13 during mid-day trading on Tuesday, reaching $5.17. The stock had a trading volume of 274,500 shares, compared to its average volume of 1,543,079. Savara has a 1 year low of $1.89 and a 1 year high of $7.01. The stock has a market cap of $1.06 billion, a PE ratio of -9.76 and a beta of 0.28. The company has a fifty day moving average price of $5.46 and a 200 day moving average price of $5.41. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 11.85.

Institutional Investors Weigh In On Savara

A number of hedge funds have recently added to or reduced their stakes in SVRA. New York State Common Retirement Fund increased its position in shares of Savara by 163.8% during the 4th quarter. New York State Common Retirement Fund now owns 36,555 shares of the company’s stock valued at $220,000 after purchasing an additional 22,700 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Savara during the 2nd quarter valued at about $201,000. Osaic Holdings Inc. increased its position in shares of Savara by 6.9% during the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock valued at $197,000 after purchasing an additional 2,098 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Savara during the 4th quarter valued at about $130,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after purchasing an additional 6,449 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. HC Wainwright reissued a “buy” rating on shares of Savara in a research report on Monday, March 16th. William Blair set a $10.00 target price on Savara in a research report on Monday, March 16th. Oppenheimer assumed coverage on Savara in a research report on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.13.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.